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Background
Animal models are critical tools for the 
preclinical evaluation of drugs. Yet in 
the HIV field, the value of such models 
for predicting the success of preventive 
drug and vaccination strategies in 
humans has been disappointing. 
For example, animal models were 
unable to predict the failure of vaginal 
microbicides in large clinical trials in 
humans [1,2]. However, two recently 
published studies have provided 
encouraging results. Using a repeat, 
low-dose exposure macaque model, 
Walid Heneine and colleagues found 
that systemic pre-exposure prophylaxis 
(PrEP), using a combination of 
the nucleoside analogue reverse 
transcriptase inhibitors emtricitabine 
and tenofovir, protected macaques 
against rectal challenge with simian 
HIV [3]. Most prior macaque studies 
used single high-dose virus challenges, 
which are less representative of viral 
exposure in humans. Another study 
by J. Victor Garcia and colleagues 
introduced an improved mouse model 
of vaginal HIV transmission [4]. Mice 
engineered to stably exhibit extensive 
infiltration of organs and tissues, 
including the female reproductive 
tract, with a broad range of human 
blood cells were protected from 
intravaginal HIV infection by PrEP with 
emtricitabine/tenofovir. This mouse 
model opened the way for larger-scale 
comparative assessments in vivo, which 
is impossible in macaques due to the 
prohibitively high costs. 
A third key study by Martin Cranage 
and colleagues is published in this 
issue of PLoS Medicine [5]. The 
researchers investigated whether rectal 
simian immunodeficiency virus (SIV) 
transmission in macaques could be 
prevented by the topical pre-exposure 
application of tenofovir gel. Rectal 
SIV or HIV challenge bears a much 
higher transmission probability than 
vaginal challenge. With some caveats, 
as discussed further below, successful 
prevention of rectal transmission 
is therefore likely to have a better 
predictive value for human trials than 
vaginal challenge models. Moreover, 
anal intercourse in heterosexual 
populations has been underestimated 
in the past, and means to prevent 
rectal HIV transmission are thus 
urgently needed for both women 
and men who have unprotected anal 
intercourse. 
The New Study
Cranage and colleagues examined 
systemic infections of macaques 
after high-dose rectal SIV challenge, 
comparing animals that received 1% 
tenofovir gel in the rectum up to two 
hours before viral challenge to animals 
that received placebo gel or remained 
untreated. Six of nine macaques given 
tenofovir per rectum were completely 
protected from infection, and another 
two animals had either persistently low 
viral loads or markedly delayed onset 
of viremia. In contrast, all untreated 
macaques and three out of the four 
macaques that were given placebo 
gel became infected, exhibiting early 
viremia and higher viral loads. Three 
additional macaques received tenofovir 
gel per rectum two hours after virus 
challenge, and two of these became 
infected.
The researchers performed two 
ancillary measurements in these 
animals. First, they quantified tenofovir 
concentrations in plasma and found 
a positive association between the 
plasma concentration 15 minutes after 
rectal tenofovir administration and 
the degree of protection. Plasma levels 
after two hours were markedly lower, 
indicating a fast peaking of plasma 
drug concentration after rectal dosing. 
Second, they measured HIV peptide-
specific, interferon gamma-secreting 
T cells in the blood and found Gag-
specific T cells (T cells recognizing 
peptides derived from the HIV core) 
in four out of seven protected animals 
that were tested. 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS
Medicine:
Cranage M, Sharpe S, Herrera C, Cope 
A, Dennis M, et al. (2008) Prevention of 
SIV rectal transmission and priming of 
T cell responses in macaques after local 
pre-exposure application of tenofovir gel. 
PLoS Med 5(8): e157. doi:10.1371/journal.
pmed.0050157
Martin Cranage and colleagues find 
that topical tenofovir gel can protect 
against rectal challenge with SIV in a 
macaque model, and can permit the 
induction of SIV-specific T cell responses.PLoS Medicine  |  www.plosmedicine.org 1184 August 2008  |  Volume 5  |  Issue 8  |  e167
Lastly, the authors adapted an in 
vitro human rectal explant model 
(tissues taken from the rectum 
are kept alive and challenged with 
virus in culture) to macaque tissue 
and demonstrated that colorectal 
explants from four SIV-naïve animals 
given tenofovir gel per rectum three 
hours prior to necropsy exhibited 
strong inhibition of viral replication. 
Inhibition was not observed in explants 
from the small intestine in the same 
animals. Correspondingly, tenofovir 
tissue concentrations were measurable 
in lysates of these colorectal tissues, 
whereas no drug was detected in lysates 
from the small intestine. 
Strengths and Limitations of the 
New Study
This is the first study showing that the 
topical application of a microbicide, 
tenofovir gel, to the rectum protects 
against a high-dose rectal challenge 
with SIV. In conjunction with the 
data in the paper on tenofovir 
pharmacokinetics and the induction 
of systemic anti-HIV cellular immunity 
by the viral challenge [5], the work will 
be informative for human microbicide 
trials.
An important limitation of the 
study is the single application/single 
challenge design. The animals received 
a single dose of topical microbicide, 
followed by a single viral challenge. 
While the observed protective effect 
of topical tenofovir gel is encouraging, 
these results should be extrapolated 
cautiously to humans. High-risk 
behavior in humans is marked by 
repeated exposures to the virus, which 
potentially will require reapplication of 
the microbicide gel numerous times, 
possibly over extended time periods. 
This reapplication in turn may lead 
to cumulative toxic damage of the 
mucosa, either by the compound 
itself or its particular formulation. 
This type of cumulative toxicity has 
been observed previously, e.g., for 
nonoxynol-9 [6], and may neutralize 
the protective effect of the microbicide 
or even increase viral transmission. 
Such a mechanism is discussed as the 
cause for the detected trend toward 
increased HIV risk that has been 
associated with cellulose sulfate use in 
two recently halted phase III clinical 
trials [2]. Moreover, the tenofovir 
gel formulation used in Cranage and 
colleagues’ study is hyperosmolar, 
and a histological assessment of its 
potentially harmful effect on mucosal 
integrity would have been interesting 
to include in the study. Hyperosmolar 
over-the-counter products have been 
shown to cause mucosal damage to the 
gastrointestinal tract [7]. This mucosal 
damage emphasizes the need to 
optimize microbicide formulations that 
are safe for vaginal and/or rectal use.
During sexual transmission in 
vivo, HIV is transported by semen, a 
vehicle that by itself has been shown 
to influence the efficiency of viral 
transmission [8]. Recent studies have 
shown that microbicides that fall into 
the polyanion class have reduced 
anti-HIV activity in the presence of 
semen [9,10], while antiretroviral 
drugs, such as tenofovir, have no loss 
of anti-HIV activity [10,11]. Therefore, 
incorporating the effect of semen 
on microbicide efficacy would be 
beneficial to preclinical animal studies 
such as the one by Cranage and 
colleagues.
The authors are to be commended 
for having developed and validated a 
combined high performance liquid 
chromatography/mass spectrometric 
method for the detection of tissue 
tenofovir and its phosphorylated active 
compounds (details of the method 
have been submitted for publication 
elsewhere). The publication of 
this method in full detail is eagerly 
awaited by the field. No reliable 
assays for measuring active tenofovir 
concentrations in tissues currently 
exist, but they are urgently needed, 
given the high interest in tenofovir 
and other antiretroviral drugs as 
potential compounds for topical PrEP. 
The underlying clinical question is 
how often the gel would need to be 
reapplied when repeated exposures 
to HIV are expected within a single 
day. Rapid pharmacokinetics of 
tenofovir in plasma does not necessarily 
translate to rapid degradation of the 
active intracellular compound in 
tissues. While the authors determined 
tenofovir concentrations in colorectal 
tissue at a single time point (three 
hours) after rectal tenofovir 
application, a time kinetic of the 
active form would have been more 
informative. Collectively, this work 
points to the need to have defined 
pharmacokinetic/pharmacodynamic
studies for distribution and retention 
of these drugs. Such studies are 
currently underway in the Microbicide 
Trials Network in humans, but animal 
studies would be able to provide more 
information because of more flexibility 
with sampling times and tissue 
collection.
Implications and Future Directions
Before moving topical tenofovir per 
rectum into a larger clinical trial in 
humans, the current study should 
be extended to two repeat-exposure 
modalities. First, a multiple tenofovir 
application/multiple virus challenge 
design will determine if repeated 
applications of the topical tenofovir 
formulation have a negative effect 
on the mucosa over time that in turn 
compromises the protective efficacy. 
Second, the interesting finding that 
viral exposure led to systemic HIV-
specific T cell immunity in most of the 
protected animals in the current study 
warrants investigation of the biological 
significance of this observation. In 
theory, these responses may be either 
beneficial, because they contribute to 
resistance to infection, or detrimental, 
because they signify T cell activation 
and thus a higher susceptibility of 
target cells in the mucosa. To help 
clarify if the emergence of these 
responses is cause for optimism or 
concern, a set of animals who have 
developed HIV-specific T cell immunity 
should be rechallenged with SIV in 
the absence of microbicide protection. 
Another lesson from this observation 
is that HIV-specific T cell responses 
should be evaluated in ongoing human 
microbicide trials. 
Topical application of antiretroviral 
compounds preceding or following 
local viral challenge could be used to 
clarify early virus trafficking in vivo. 
For example, one can tentatively 
conclude from this study that intact 
virions sequestered in endosomal 
compartments of cells do not 
significantly contribute to infection. 
Since tenofovir acts after viral fusion, 
breakthrough infections due to 
migration of dendritic cells harboring 
sequestered virions to sites with low 
or absent tenofovir levels would be 
expected to occur both for pre- and 
post-exposure application of the drug. 
The data from this study, while limited, 
indicate that post-exposure application 
is less effective in protecting against 
infection. This finding suggests that 
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in the mucosa, followed by migration 
of these productively infected cells 
to more distant sites, may be the 
reason for infection, a finding that is 
supported by our own ex vivo studies 
of mucosal HIV invasion [12]. Studies 
using skin Langerhans cells have indeed 
provided evidence that endocytosis 
of virions via langerin results in viral 
degradation rather than preservation 
of infectivity [13]. Thus sequestration 
of virus in mucosal dendritic cells, 
which clearly occurs [12], likely leads 
to cross-presentation of viral antigens, 
as evidenced by the measured CD8+ T 
cell responses, but not to the spread of 
productive infection. 
Going forward, algorithms should be 
developed that rely on a combination 
of approaches to evaluate microbicide 
safety and effectiveness. Many may 
want to take advantage of the recently 
published improved animal models 
[3–5] to more fully define their 
microbicide candidate. Well-designed 
pharmacokinetic/pharmacodynamic
studies would help to determine how 
far these drugs are distributed as 
well as how long they are retained. 
Clearly, future microbicide trials 
need to be based on solid preclinical 
evidence of safety and efficacy. Animal 
studies should not be done ex post 
facto because this can open the door 
to a gamut of issues, ranging from 
unpleasant surprises when anticipated 
efficacy is lacking to subconscious 
investigator bias. The current models 
should be refined, validated by testing 
compounds that have lacked efficacy 
in large human trials (e.g., cellulose 
sulfate, Carraguard, and SAVVY), and 
then used to their fullest potential as 
decision tools to determine if investing 
human and financial resources into a 
large clinical trial is warranted.  
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